A randomized, prospective, multicenter study of bevacizumab vs. ranibizumab for choroidal neovascularization in myopia
Latest Information Update: 13 Jun 2016
At a glance
- Drugs Bevacizumab (Primary) ; Ranibizumab (Primary)
- Indications Choroidal neovascularisation; Myopia
- Focus Therapeutic Use
- 13 Jun 2016 New trial record
- 31 May 2016 Results published in the Pediatric Infectious Disease Journal